Home › Employers › Ascidian Therapeutics, Inc.
Ascidian Therapeutics, Inc.: H-1B salaries and sponsorship
Ascidian Therapeutics, Inc. filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 4. Median offered salary: $99,111.
Does Ascidian Therapeutics, Inc. sponsor H-1B visas?
Ascidian Therapeutics, Inc. filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Apr 10, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Senior Associate Scientist | 3 | $100,000 |
| Associate Scientist II | 1 | $92,700 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 3 | $100,000 |
| FY2025 | 1 | $92,700 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Associate Scientist II | $92,700 Level I | Boston, MA | Apr 10, 2025 | Oct 1, 2025 | Certified |
| Senior Associate Scientist | $101,168 Level II | Boston, MA | Apr 19, 2024 | Oct 1, 2024 | Certified |
| Senior Associate Scientist | $100,000 Level II | Boston, MA | Apr 19, 2024 | Apr 29, 2024 | Certified |
| Senior Associate Scientist | $98,222 Level I | Boston, MA | Apr 11, 2024 | Oct 1, 2024 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).